We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 1,631

Follow-on innovation or evergreening: what is the difference?
  • Davies Collison Cave
  • Australia
  • January 17 2017

While the terms “evergreening patent” and “follow-on patent" are both used to refer to patents that protect pharmaceutical formulations, new forms of


Inventorship - a muddy concept at best
  • FB Rice
  • Australia
  • January 16 2017

Inventorship has been described as “one of muddiest concepts in the muddy metaphysics of the patent law”. Mueller Brass Co. v. Reading Industries, Inc


Federal Court Rules That Overseas Manufacture Will Not Avoid Infringement Of Australian Swiss Claims
  • Bird & Bird
  • Australia
  • January 11 2017

A recent decision in the Federal Court of Australia has confirmed that the importation and sale of a medicament manufactured overseas will constitute


Missed a patent deadline in Australia? It may not be as bad as you think.
  • FPA Patent Attorneys
  • Australia
  • January 10 2017

Australian patent law is quite generous when it comes to extensions of time. Where a deadline is missed due to a genuine error or omission, it is


The meaning of Myriad
  • Davies Collison Cave
  • Australia
  • January 9 2017

Before you can qualify for patent protection in Australia, and before you need to worry about the normal requirements of novelty and inventive step


December 2016 International Trade Compliance
  • Baker McKenzie
  • Global, OECD, United Kingdom, USA, Australia, Canada, European Union
  • December 12 2016

On 29 November 2016, the WTO reported that most WTO members welcomed Ecuador’s efforts to lower its import surcharge rates and reduce the number of


A comparative study of strategies for patenting human therapeutics in the Asia Pacific Region: IP In Depth
  • Fisher Adams Kelly Callinans
  • Asia-Pacific, Australia
  • December 9 2016

In the last century, innovations in the life sciences have allowed for treatment and prevention of numerous diseases and disorders, enabling higher


Recent Patent Office decision provides further clarity in patentability of nucleic acids in Australia
  • Fisher Adams Kelly Callinans
  • Australia
  • December 9 2016

As has been widely reported, including in our previous articles such as this, the patentability or otherwise of isolated nucleic acids has been a


Survey of the Safe Harbor in the United States and Europe
  • Fish & Richardson PC
  • Australia, European Union, United Kingdom, USA
  • December 7 2016

On October 3, 2016, the United States Supreme Court denied Amphastar Pharmaceutical's petition for certiorari regarding the so-called "safe harbor,"


Parameteritis pokes holes in Swiss-type claim
  • Minter Ellison
  • Australia
  • December 2 2016

The Full Federal Court has recently handed down its decision in the appeal by Otsuka Pharmaceutical Co (Otsuka) against the earlier finding by